William D. Clark was appointed as a member of our Board of Directors in August 2021 and has served as Chairperson of the Board since November 1, 2022.

filing / Sep 4, 2026 / receipt

Gary Sender was appointed as a member of our Board of Directors in October 2020 and served as the Lead Independent Director of the Board of Directors from December 2021 until November 10, 2022

filing / Sep 4, 2026 / receipt

Class I Directors David Arkowitz 64 Class I Director

filing / Sep 4, 2026 / receipt

The Company’s bank requires an additional 5 % collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card.

filing / Aug 28, 2026 / receipt

Restricted cash consists of a letter of credit obtained related to the San Diego operating lease (see Note 15 - Operating Lease Obligations) and a Company purchasing card.

filing / Aug 28, 2026 / receipt

Based on our evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of June 30, 2026.

filing / Aug 28, 2026 / receipt

iBio has leased lab and office space in San Diego for the purpose of conducting research. For the fiscal years 2026 and 2025, iBio spent $19.6 million and $8.3 million, respectively, in R&D related activities.

filing / Aug 28, 2026 / receipt

On September 11, 2021, iBio entered into a lease with SAN DIEGO INSPIRE 4, LLC for approximately 11,383 square feet of laboratory and office space at 11750 Sorrento Valley Road in San Diego, CA.

filing / Aug 28, 2026 / receipt

The Company’s bank requires an additional 5 % collateral held above the actual letter of credit issued for the San Diego lease and Company purchasing card.

filing / May 12, 2026 / receipt

Depreciation expense reported was approximately $ 148,000 and $ 122,000 for the three months ended March 31, 2026 and 2025, respectively.

filing / May 12, 2026 / receipt

Molly Carr is our chief medical officer. She joined the company five weeks ago and we made it really hard on us because we wanted somebody who has experience across the entire development stage. She h

company_statement / Sep 4, 2026 / receipt

So obviously we're looking for clinical operations. We're looking for regulatory. We're looking for medical affairs and all of the team we're putting together right now to successfully and rapidly dev

company_statement / Sep 4, 2026 / receipt